Core Viewpoint - The company emphasizes its commitment to a strategic goal of being a health enterprise focused on traditional Chinese medicine and innovation, aiming for sustainable development and enhanced market recognition [1] Group 1 - The company is dedicated to strengthening its core capabilities and improving operational performance to ensure stable growth [1] - The focus remains on the research and development of innovative drugs to increase the company's visibility and reputation in the capital market [1] - The company aims to maintain a positive brand image in the capital market, ensuring the protection of investor interests and delivering better returns to shareholders [1]

Core Viewpoint - Zhongsheng Pharmaceutical has developed Anglavei tablets, the world's first RNA polymerase PB2 protein inhibitor for influenza, which has shown superior efficacy compared to existing antiviral drugs [1] Group 1: Product Information - Anglavei tablets have a clear mechanism of action and global intellectual property rights, specifically targeting adult patients with uncomplicated type A influenza [1] - In vitro virology studies indicate that Anglavei demonstrates significantly better inhibition of various type A influenza viruses compared to neuraminidase inhibitors like Oseltamivir and endonuclease inhibitors like Baloxavir [1] - Anglavei is effective against Oseltamivir-resistant strains, Baloxavir-resistant strains, and highly pathogenic avian influenza virus strains [1] Group 2: Clinical Trials and Approval - The Phase III clinical trial comparing Anglavei with Oseltamivir capsules and a placebo for adult type A influenza patients has yielded positive results, meeting the predefined primary efficacy endpoints with good safety [1] - Anglavei tablets have received approval from the National Medical Products Administration, and the company is actively advancing the commercialization of this product [1]

Core Points - Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced the receipt of a patent certificate from the Japan Patent Office for an invention titled "Ketone Amide Derivatives and Their Applications" [1] Company Summary - The patent was granted to Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., a subsidiary of Guangdong Zhongsheng Pharmaceutical [1]

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced that its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has received a patent certificate from the Japan Patent Office for a key compound related to its oral antiviral drug, Lairuitai Tablets, which is the first oral monotherapy for COVID-19 [1][2]. Group 1: Patent Details - The patent is for "ケトアミド誘導体およびその用途" (Ketamide derivatives and their applications) with patent number 7735531, applied on September 5, 2022, and valid for 20 years from the application date [1]. - The patent is considered a core patent for Lairuitai Tablets, which effectively reduces viral load, shortens the time to viral clearance, and alleviates clinical symptoms [1]. Group 2: Market Implications - The acquisition of this core patent enhances the company's intellectual property protection system and supports the promotion of Lairuitai Tablets in overseas target markets [2]. - The patent authorization is not expected to have a significant impact on the company's short-term financial status or operating performance [2].

Group 1 - The core point of the article is that Zhongsheng Pharmaceutical has announced that its subsidiary has received a patent certificate from the Japan Patent Office for an invention titled "Ketone Amide Derivatives and Their Applications" [1]

证券代码：002317 公告编号：2025-099 广东众生药业股份有限公司 关于控股子公司获得日本专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广东众生药业股份有限公司（以下简称"公司"）控股子公司广东众 生睿创生物科技有限公司（以下简称"众生睿创"）收到日本特许厅（Japan Patent Office）颁发的专利证书。具体情况如下： 发明名称：ケトアミド誘導体およびその用途（酮酰胺衍生物及其应用） 专利号：7735531 专利申请日：2022 年 09 月 05 日 专利权人：广东众生睿创生物科技有限公司 专利权期限：自申请日起二十年 本专利是众生睿创口服抗新型冠状病毒感染新药来瑞特韦片（商品名：乐睿 灵®）的化合物专利，属于该项目的核心专利。来瑞特韦片是全球首个拟肽类 3CL 单药抗新冠病毒感染口服药物，能够快速降低病毒滴度、缩短病毒转阴时间、缓 解临床症状，疗效显著。与其他组合包装 3CL 口服抗新冠药物相比，其单药应 用无需考虑基础疾病患者合并利托那韦用药的风险，安全性高。来瑞特韦片在 2024 年列入《抗新型冠状病毒小分子 ...

Market Overview - A-shares experienced a slight increase with reduced trading volume, while government bond futures rose across the board [1][2] - The technology sector showed strong performance, leading the market with significant gains in the ChiNext and STAR Market indices [2][3] Stock Market Analysis - The Shanghai Composite Index rose by 0.22% to 3828.58 points, with the ChiNext Index increasing by 0.55% and the STAR Market gaining 3.38% [2] - Total trading volume in A-shares was 2.14 trillion yuan, down from 2.35 trillion yuan the previous day [2] - The technology sector remained the market's main focus, with notable declines in several weight-loss drug stocks [2] Bond Market Analysis - Government bond futures showed a "short weak long strong" pattern, with the 30-year contract rising by 0.22% and the 10-year contract by 0.20% [5] - The People's Bank of China (PBOC) resumed 14-day reverse repos, injecting 300 billion yuan into the market, contributing to a net injection of 260.5 billion yuan for the day [5][6] Commodity Market Analysis - Precious metals performed strongly, with silver rising by 3.81% and gold by 2.01%, driven by expectations of continued monetary easing [7] - The shipping index increased by 2.00%, while most basic metals saw gains, including tin and copper [7] Policy and Economic Outlook - The State Council's new policies aim to stabilize the capital market, with a focus on the technology sector, which now accounts for over 25% of A-share market capitalization [3] - The Ministry of Industry and Information Technology introduced a plan for the steel industry, targeting an average annual growth of 4% over the next two years, emphasizing structural adjustments and high-quality development [9] Trading Hotspots - Key sectors to watch include rare metals, artificial intelligence, domestic chips, and consumer goods, driven by factors such as central bank policies and economic recovery [11][12] - The current market environment suggests a potential "dual bull" scenario for both stocks and bonds, with a focus on sectors benefiting from monetary easing and policy support [12]

Core Insights - The stock of Zhongsheng Pharmaceutical experienced a decline of 6.28% with a trading volume of 1.843 billion yuan and a volatility of 17.24% on the day [2] - Institutional investors net sold 225 million yuan, while the Shenzhen Stock Connect saw a net purchase of approximately 52.5 million yuan [2] - Over the past five days, the main capital outflow from the stock totaled 257 million yuan [2] Trading Activity - The stock's trading data indicated a total turnover of 742 million yuan among the top five trading departments, with a net selling amount of 164 million yuan [2] - The top buying department was the Shenzhen Stock Connect, which had a net purchase of 52.5 million yuan, while the largest selling department also belonged to the Shenzhen Stock Connect [2] - Specific trading details showed that seven institutional special seats participated, with a total buying amount of 86.89 million yuan and a selling amount of 312 million yuan, resulting in a net selling of 225 million yuan [2] Margin Trading Data - As of September 19, the margin trading balance for the stock was 527 million yuan, with a financing balance of 525 million yuan and a securities lending balance of 252.73 thousand yuan [3] - Over the past five days, the financing balance decreased by 58.9 million yuan, representing a decline of 10.10%, while the securities lending balance decreased by 40.45 thousand yuan, a decline of 13.80% [3] - Detailed trading information on September 22 showed significant buying and selling activity from various institutional and retail departments [3]

Core Viewpoint - On September 22, a total of 38 stocks were involved with institutional investors, with 17 stocks showing net buying and 21 stocks showing net selling [1][2]. Institutional Net Buying - The top three stocks with the highest net buying by institutions were: - Kaipu Cloud: Net buying amount of 1.507 billion yuan, with a price increase of 14.56% [2] - Jucheng Co., Ltd.: Net buying amount of 359 million yuan, with a price increase of 15.35% [2] - Chip Origin: Net buying amount of 273 million yuan, with a price increase of 17.34% [2] Institutional Net Selling - The top three stocks with the highest net selling by institutions were: - Luxshare Precision: Net outflow amount of 281 million yuan [1] - Zhongsheng Pharmaceutical: Net outflow amount of 225 million yuan [1] - Jingxing Paper: Net outflow amount of 129 million yuan [1]

Group 1 - The stock of Zhongsheng Pharmaceutical (002317.SZ) fell by 6.28% today, with a turnover rate of 12.79% and a transaction volume of 1.843 billion yuan [1] - The net buying from the Shenzhen Stock Connect was 52.5 million yuan, with total purchases of 180 million yuan and sales of 128 million yuan [1] - Seven institutions collectively bought 86.89 million yuan and sold 312 million yuan, resulting in a net sell of 22.5 million yuan [1] Group 2 - The top five buying entities included the Shenzhen Stock Connect with 180.28 million yuan, accounting for 9.78% of total transactions [1] - The largest selling entity was also the Shenzhen Stock Connect, with the same amount of 180.28 million yuan, representing 9.78% of total transactions [1] - Institutional trading was significant, with multiple entries showing a total of 31.77 million yuan and 31.70 million yuan in buying, but no sales recorded [1]